William Blair Issues Positive Estimate for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at William Blair boosted their Q3 2025 EPS estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 1st. William Blair analyst L. Hanbury-Brown now expects that the company will earn $1.46 per share for the quarter, up from their prior forecast of ($0.51). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at $0.05 EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.77) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter last year, the business posted ($0.54) earnings per share. The company's revenue for the quarter was down 3.2% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald started coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 price objective on the stock. Scotiabank decreased their price objective on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. Bank of America cut shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $41.00 to $23.00 in a research note on Friday, May 9th. Wells Fargo & Company lifted their price objective on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research note on Monday, June 2nd. Finally, Mizuho decreased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $39.79.

Apellis Pharmaceuticals Stock Performance

APLS stock traded up $0.17 during mid-day trading on Friday, hitting $17.99. 891,120 shares of the company were exchanged, compared to its average volume of 2,351,659. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $42.47. The business has a 50 day simple moving average of $18.15 and a 200-day simple moving average of $23.52. The stock has a market capitalization of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67. The company has a current ratio of 4.08, a quick ratio of 3.62 and a debt-to-equity ratio of 2.76.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in APLS. US Bancorp DE raised its position in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after acquiring an additional 1,327 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Apellis Pharmaceuticals by 2.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 115,045 shares of the company's stock worth $3,671,000 after acquiring an additional 2,250 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Apellis Pharmaceuticals by 4.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 996,748 shares of the company's stock worth $31,806,000 after purchasing an additional 40,386 shares during the period. Victory Capital Management Inc. grew its stake in Apellis Pharmaceuticals by 36.5% during the fourth quarter. Victory Capital Management Inc. now owns 562,269 shares of the company's stock worth $17,942,000 after purchasing an additional 150,363 shares during the period. Finally, M&T Bank Corp acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth approximately $216,000. 96.29% of the stock is currently owned by institutional investors.

Insider Activity

In other news, General Counsel David O. Watson sold 5,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the transaction, the general counsel directly owned 133,730 shares in the company, valued at $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.50% of the stock is owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).